Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUBAIN vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
3.5–5 hours (terminal elimination half-life); clinically, in hepatic or renal impairment, half-life may be prolonged, requiring dose adjustment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via glucuronidation; CYP450 isoenzymes are not significantly involved.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (83% as unchanged drug and glucuronide conjugate); fecal excretion accounts for <5%.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 25–30% bound to plasma proteins (mainly albumin).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
4–6 L/kg; indicates extensive tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability is low (<20%) due to extensive first-pass metabolism; IV, IM, and subcutaneous routes provide 100% bioavailability.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl 30-50 m L/min: reduce dose by 50% and administer every 6 hours; Cr Cl <30 m L/min: reduce dose by 75% and administer every 8 hours.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class B: reduce dose by 50% and administer every 6 hours; Child-Pugh Class C: reduce dose by 75% and administer every 8 hours.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Children ≥1 year: 0.1-0.2 mg/kg IV, IM, or SC every 3-6 hours as needed; maximum single dose 20 mg.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at 50% of the usual adult dose (5-10 mg) and titrate cautiously; maximum single dose 15 mg due to increased sensitivity and risk of respiratory depression.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of interactions with drugs affecting CYP3A4; risk of serotonin syndrome with concurrent use of serotonergic drugs.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression,Increased intracranial pressure,Hepatic or renal impairment,Biliary tract disease,Concurrent CNS depressants,Opioid dependence (may precipitate withdrawal),Elderly and debilitated patients
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to nalbuphine or any component,Current or suspected opioid dependence (may precipitate acute withdrawal)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. Avoid grapefruit juice as it may affect metabolism of certain opioids, though no direct evidence with nalbuphine.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Pregnancy Category C. First trimester: insufficient human data; animal studies show increased skeletal anomalies at high doses. Second and third trimesters: prolonged use may cause neonatal opioid withdrawal syndrome (NOWS); avoid chronic use due to risk of respiratory depression in neonate.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted in breast milk; M/P ratio unknown. Use caution due to potential for infant sedation and respiratory depression. American Academy of Pediatrics considers use compatible but monitor for drowsiness and feeding difficulties.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No established dose adjustment guidelines. Pregnancy may increase clearance of opioids; however, Nubain (nalbuphine) has not been systematically studied for pharmacokinetic changes in pregnancy. Use lowest effective dose for shortest duration, avoiding chronic use. In labor, use 10–20 mg IV/IM every 3–6 hours as needed; titrate to maternal pain with fetal monitoring.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
NUBAIN (nalbuphine) is a mixed agonist-antagonist opioid; it can precipitate withdrawal in opioid-dependent patients. It has a ceiling effect for respiratory depression, making it safer than pure agonists in high doses. Onset of action is 2-3 minutes IV, 15 minutes IM/SC; duration is 3-6 hours. Reversal of opioid effects may require higher doses of naloxone due to nalbuphine's strong receptor binding.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they can increase side effects like drowsiness or slow breathing.,Do not drive or operate machinery until you know how NUBAIN affects you; it may cause dizziness or drowsiness.,Do not stop abruptly; withdrawal symptoms may occur (anxiety, sweating, nausea).,If you have a history of opioid dependence, inform your doctor; NUBAIN may cause withdrawal symptoms.,Report any signs of allergic reaction (rash, itching, swelling) or difficulty breathing immediately.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUBAIN vs ABSTRAL, answered by our medical review team.
NUBAIN is a Opioid Analgesic that works by Nalbuphine is a mixed opioid agonist-antagonist. It acts as an agonist at kappa opioid receptors and as an antagonist at mu opioid receptors, providing analgesia with a ceiling effect for respiratory depression.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUBAIN and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUBAIN is: 10-20 mg IV, IM, or SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum daily dose 160 mg.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUBAIN and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUBAIN is classified as Category C. Pregnancy Category C. First trimester: insufficient human data; animal studies show increased skeletal anomalies at high doses. Second and third trimesters: prolonged use may cause. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.